End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.63 CNY | +3.19% | +4.04% | -20.16% |
04-26 | Aier Eye Hospital Group Co., Ltd. Announces Profit Distribution Proposal for 2023 | CI |
04-26 | Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an expected P/E ratio at 30.22 and 22.33 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.16% | 16.21B | B+ | ||
+4.50% | 12.44B | B | ||
+3.98% | 11.58B | B+ | ||
+9.72% | 10.79B | B+ | ||
+23.61% | 8.26B | B | ||
-2.19% | 7.68B | A- | ||
+20.75% | 7.2B | D | ||
+4.49% | 6.67B | B- | ||
+50.89% | 4.66B | - | ||
-5.01% | 4.25B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300015 Stock
- Ratings Aier Eye Hospital Group Co., Ltd.